Product Description
Liraglutide is a derivative of GLP?1 and shares 97% amino acid sequence homology with its parent molecule 9. GLP?1 is a polypeptide incretin hormone secreted by the L?cells of the gastrointestinal tract in response to nutrients in the lumen. It causes a glucose dependent stimulation of insulin secretion 10, reduction in plasma glucagon concentrations 11, delayed gastric emptying 12, appetite suppression 13, 14, and an increase in heart rate (Fig. 1) 15.
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: Hypertension | Dyslipidemia | General Diabetes | Type 2 Diabetes | Overweight | Weight Loss | General Diabetes | Type 2 Diabetes
Known Adverse Events: Abdominal Pain | Dizziness | Headache | Pain Unspecified | Enteritis | Gastroenteritis | Hypoglycemia | Constipation | Diarrhea | Dyspepsia | Urticaria
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, Germany, Hong Kong, India, Israel, Malaysia, Mexico, Portugal, Russia, Switzerland, United States, Unknown Location
Active Clinical Trial Count: 24
Highest Development Phases
Phase 3: Obesity|Overweight|Type 2 Diabetes
Phase 2: Parkinson's Disease|Smoking Cessation|Tobacco Use Disorder
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NN8022-4392 | P3 |
Unknown Status |
Obesity |
2027-01-15 |
|
| THDB0213L03 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2025-10-01 |
|
| 2018-002425-34 | P2 |
Active, not recruiting |
Type 2 Diabetes |
2024-11-20 |
|
| NEX-22-01 | P1 |
Active, not recruiting |
Type 2 Diabetes |
2024-11-01 |